Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

This article was originally published in The Pink Sheet Daily

Executive Summary

The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.
Advertisement

Related Content

Incyte's Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing
Incyte’s Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing
Novartis/Incyte Move Forward With JAK Inhibitor For MF
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
Early Data On JAK Inhibitor Show Incyte And Lilly Are In The Race In Rheumatoid Arthritis
Novartis Offers $120 Million For Corthera Eyeing Phase III Acute Cardiology Product
With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis
Deals Of The Week: Clovis/Clavis; Novartis/Incyte; Jubilant/UAB/SRI ...
Incyte Will First Seek Myelofibrosis, Rheumatoid Arthritis Indications For Lead JAK Compound

Topics

Advertisement
UsernamePublicRestriction

Register

PS068810

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel